Skip to main content

Search

Reset all filters
67 Result(s)
Sort by

Cancer cell directed therapies

Cancer cell directed therapies

At Boehringer Ingelheim, we are investigating cancer cell directed therapies that target key cancer drivers and hallmarks to directly kill cancer cells.
Immune cell directed therapies

Immune cell directed therapies

Boehringer Ingelheim is committed to transforming cancer care, investigating therapies that target cancer cells and boost the immune system for the benefit of patients.
Innovation in Oncology and Cancer Immunology Research

Innovation in Oncology and Cancer Immunology Research

We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.
Cancer

Cancer

At Boehringer Ingelheim we are dedicated to working on improving treatments for cancer patients everywhere with a focus on lung and gastrointestinal cancers.
Lung Cancer

Lung Cancer

Building on our experience in lung disease, our goal is to take lung cancer on, transform the treatment landscape and ultimately, redefine all lung cancers as curable.
Computational Biology & Digital Sciences

Computational Biology & Digital Sciences

At Boehringer Ingelheim, we are investing into the power of computational biology and data sciences to accelerate the journey from scientific discoveries to breakthrough therapies.
Oncology Translational Science

Oncology Translational Science

Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts
Testing New Treatments for NF1

Testing New Treatments for NF1

The Medical University of Vienna and Boehringer Ingelheim have taken an innovative approach to the development of ways of treating NF1-associated tumors.
Research at the Regional Center Vienna

Research at the Regional Center Vienna

The Regional Center Vienna counts for 33 countries and has been a central pillar in Boehringer Ingelheim’s global research network.
Patients in Focus

Patients in Focus

Boehringer Ingelheim RCV provides over six million patients with innovative therapies. Ensuring that the patients’ needs at every stage are met precisely is of decisive importance.
Lung Diseases

Lung Diseases

Find information on a variance of respiratory diseases such as asthma, COPD, idiopathic pulmonary fibrosis (IPF), Scleroderma and lung cancer.
Biotherapeutics Discovery

Biotherapeutics Discovery

Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
The Oscars of Science

The Oscars of Science

Revolutionary advances in physics and chemistry used at Boehringer Ingelheim
Small Molecule Drug Discovery

Small Molecule Drug Discovery

Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.
Research Institute of Molecular Pathology IMP

Research Institute of Molecular Pathology IMP

Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.